Study S001197

Adding Liraglutide to the Backbone Therapy of Biguanide in Patients With Coronary Artery Disease and Newly Diagnosed Type-2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01595789
Acronym: AddHope2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 41
Start: 2012-05
Primary completion: 2014-10
Lead sponsor: Haugaard, Steen Bendix, M.D., DMSc
Conditions: Coronary Artery Disease; Diabetes Mellitus, Type 2
Interventions: DRUG:Liraglutide; DRUG:Placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2011-005405-78

Registered primary outcomes

Beta-cell function [after 12 weeks of intervention]
LVEF [after 12 weeks of intervention]

Linked records (6)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0019221	Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study. Kumarathurai P, Cardiovascular diabetology	2021	Randomized trial	PMID 33413428 DOI	cites ClinicalTrials.gov:NCT01595789; registry reference DERIVED:33413428
R0013449	Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. Anholm C, Diabetology & metabolic syndrome	2019	Randomized trial	PMID 31164926 DOI	cites ClinicalTrials.gov:NCT01595789; registry reference DERIVED:31164926
R0011803	Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study. Kumarathurai P, Journal of hypertension	2017	Randomized trial	PMID 28129251 DOI	cites ClinicalTrials.gov:NCT01595789; registry reference DERIVED:28129251
R0012790	Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. Kumarathurai P, Diabetes care	2017	Randomized trial	PMID 27797930 DOI	cites ClinicalTrials.gov:NCT01595789; registry reference DERIVED:27797930
R0013754	Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study. Kumarathurai P, Cardiovascular diabetology	2016	Randomized trial	PMID 27455835 DOI	cites ClinicalTrials.gov:NCT01595789; registry reference DERIVED:27455835
R0022206	Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol. Anholm C, BMJ open	2014	Protocol	PMID 25031198 DOI	cites ClinicalTrials.gov:NCT01595789; cites EudraCT:2011-005405-78; registry reference DERIVED:25031198